11,380 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Convergence Investment Partners LLC

Convergence Investment Partners LLC acquired a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 11,380 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,935,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Pinnacle Associates Ltd. boosted its holdings in Jazz Pharmaceuticals by 0.7% in the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after purchasing an additional 83 shares during the period. Moneco Advisors LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at $208,000. Swiss Life Asset Management Ltd boosted its holdings in Jazz Pharmaceuticals by 50.1% in the 4th quarter. Swiss Life Asset Management Ltd now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $687,000 after purchasing an additional 1,349 shares during the period. LRI Investments LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at $38,000. Finally, Crossmark Global Holdings Inc. boosted its holdings in Jazz Pharmaceuticals by 68.4% in the 4th quarter. Crossmark Global Holdings Inc. now owns 6,187 shares of the specialty pharmaceutical company’s stock valued at $1,052,000 after purchasing an additional 2,513 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $228.77 on Friday. The company’s fifty day moving average price is $197.18 and its 200-day moving average price is $176.51. The firm has a market capitalization of $14.35 billion, a price-to-earnings ratio of -11,432.78, a PEG ratio of 0.41 and a beta of 0.27. Jazz Pharmaceuticals PLC has a one year low of $105.00 and a one year high of $235.00. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The firm had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. On average, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 20.75 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 5,343 shares of the stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $194.49, for a total value of $1,039,160.07. Following the transaction, the senior vice president owned 28,728 shares of the company’s stock, valued at $5,587,308.72. This represents a 15.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Norbert G. Riedel sold 3,415 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $192.00, for a total transaction of $655,680.00. Following the completion of the transaction, the director directly owned 7,024 shares in the company, valued at $1,348,608. The trade was a 32.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 74,015 shares of company stock worth $14,180,486. Company insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Friday, March 27th. Robert W. Baird set a $252.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Piper Sandler raised their price target on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the company an “overweight” rating in a report on Thursday, March 19th. Royal Bank Of Canada raised their price target on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Finally, Leerink Partners raised their price target on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $230.56.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.